2016-11-22 |
1 |
|
method-of-use patent, and U.S. Patent Nos.
6,287,599 (‘599 Patent) and 6,811,794 (‘794 Patent), which cover…Shire’s Intuniv patent portfolio consists of U.S. Patent Nos. 5,854,290 (‘290
Patent), which is a now-invalidated…applied a patent procurement strategy known as “evergreening.”
“Evergreened” patents are patents not on …method-of-use patent (‘290 Patent) of guanfacine hydrochloride and two
extended release formulation patents (‘599…-of-Use Patent
57. Shire asserted all three (3) patents, including the ‘290 Patent, against |
External link to document |
2017-10-31 |
102 |
|
5,854,290 (the ’290 patent), 6,287,599 (the
’599 patent), and 6,811,794 (the ’794 patent), the terms of which…5,854,290 (the ’290 patent), 6,287,599 (the ’599
patent), and 6,811,794 (the ’794 patent), the terms of which…that ’290 patent
was a method-of-use patent. Shire denies any characterization of those patents, and denies…under three patents that covered Intuniv and that
were listed in the Orange Book: U.S. Patent Nos. 5,854,290…under three patents that cover Intuniv and that were
listed in the Orange Book: U.S. Patent Nos. 5,854,290 |
External link to document |
2020-10-09 |
343 |
Memorandum & Order |
“the ’290 Patent”), 4 6,287,599
(“the ’599 Patent”), 5 and 6,811,794 (“the ’794 Patent” and, collectively…collectively with the ’290 Patent and
the ’599 Patent, “the Patents”). 6 [FWK 380-1 ¶ 26; FWK 374-1 ¶ 3].
…hearing on the Patents on February 14, 2012. [FWK No. 380-1 ¶ 37].
The ’599 Patent and ’794 Patent each reference…Shire listed three patents in the FDA
Orange Book as covering Intuniv: U.S. Patent Nos. 5,854,290 (“the…’290 Patent in March 2012. [FWK 380-1 ¶ 27; FWK 374-1 ¶ 19].
Plaintiffs maintain that the patent was abandoned |
External link to document |